Glenmark Pharmaceuticals Ltd Financial Statement
*All values are in Rs. Cr
| Particulars | Sep 2024 | Jun 2024 | Mar 2024 |
|---|---|---|---|
| Revenue | 2,719.18 | 2,385.19 | 8,081.41 |
| Operating Expense | 1,857.47 | 1,698.44 | 1,650.78 |
| Net Profit | 595.06 | 453.73 | 4,613.70 |
| Net Profit Margin | 21.88 | 19.02 | 57.09 |
| Earning Per Share | 21.09 | 16.08 | 163.50 |
| EBIDTA | 800.17 | 630.15 | 5,804.87 |
| Effective Tax Rate | 16.07 | 15.72 | 16.41 |
| Particulars | Sep 2024 |
|---|---|
| Revenue | 2719.18 |
| Operating Expense | 1857.47 |
| Net Profit | 595.06 |
| Net Profit Margin | 21.88 |
| Earning Per Share | 21.09 |
| EBIDTA | 800.17 |
| Effective Tax Rate | 16.07 |
Invest in Glenmark Pharmaceuticals Ltd
₹0 Brokerage*
Open Demat Account
*By signing up you agree to our Terms and Conditions
*All values are in Rs. Cr
Standalone
Consolidated
| Particulars | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|
| Total Revenue Annual | 7,891.12 | 8,220.66 | 8,141.58 |
| Operating Expenses Annual | 6,649.46 | 6,747.90 | 6,453.36 |
| Operating Profit Annual | 7,480.02 | 1,962.84 | 2,733.18 |
| Interest Annual | 277.11 | 206.82 | 236.04 |
| Depreciation | 202.16 | 184.15 | 159.70 |
| Net Profit Annual | 5,167.29 | 1,208.77 | 1,997.79 |
| Tax Annual | 1,833.46 | 363.11 | 339.66 |
| Particulars | Mar 2024 |
|---|---|
| Total Revenue Annual | 7,891.12 |
| Operating Expenses Annual | 6,649.46 |
| Operating Profit Annual | 7,480.02 |
| Interest Annual | 277.11 |
| Depreciation | 202.16 |
| Net Profit Annual | 5,167.29 |
| Tax Annual | 1,833.46 |
*All values are in Rs. Cr
Standalone
Consolidated
| Particulars | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|
| Cash Flow at the Beginning | 92.70 | 28.65 | 14.72 |
| Cash Flow from Operations | -495.45 | 1,474.06 | 1,216.07 |
| Cash Flow from Investing | 3,197.17 | -431.52 | -897.02 |
| Cash Flow from Financing | -2,666.45 | -978.50 | -305.12 |
| Cash Flow at the End | 127.96 | 92.70 | 28.65 |
| Particulars | Mar 2024 |
|---|---|
| Cash Flow at the Beginning | 92.70 |
| Cash Flow from Operations | -495.45 |
| Cash Flow from Investing | 3,197.17 |
| Cash Flow from Financing | -2,666.45 |
| Cash Flow at the End | 127.96 |
*All values are in Rs. Cr
Standalone
Consolidated
| Particulars | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|
| PBDIT Margin (%) | 30.54 | 29.84 | 28.29 |
| PBIT Margin (%) | 27.98 | 27.60 | 26.33 |
| PBT Margin (%) | 27.88 | 27.47 | 26.22 |
| Net PROFIT Margin (%) | 65.48 | 14.70 | 24.54 |
| Return On Networth / Equity (%) | 6.98 | 9.12 | 10.42 |
| Return On Networth /Employed (%) | 9.75 | 10.79 | 10.93 |
| Return On Assets (%) | 22.92 | 5.73 | 10.06 |
| Total Debt / Equity (X) | 0.10 | 0.20 | 0.24 |
| Asset Turnover Ratio (%) | 0.35 | 0.39 | 0.41 |
| Particulars | Mar 2024 |
|---|---|
| PBDIT Margin (%) | 30.54 |
| PBIT Margin (%) | 27.98 |
| PBT Margin (%) | 27.88 |
| Net PROFIT Margin (%) | 65.48 |
| Return On Networth / Equity (%) | 6.98 |
| Return On Networth /Employed (%) | 9.75 |
| Return On Assets (%) | 22.92 |
| Total Debt / Equity (X) | 0.10 |
| Asset Turnover Ratio (%) | 0.35 |
*All values are in Rs. Cr
Standalone
Consolidated
| Particulars | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|
| Fixed Assets Annual | 1,778.42 | 1,759.21 | 1,760.20 |
| Total Current Assets Annual | 4,681.47 | 4,386.48 | 4,402.93 |
| Non Current Assets Annual | 22,732.92 | 20,199.44 | 18,511.56 |
| Total Shareholders Funds Annual | 22,970.62 | 17,877.46 | 16,738.59 |
| Total Assets Annual | 27,414.39 | 24,585.92 | 22,914.48 |
| Particulars | Mar 2024 |
|---|---|
| Fixed Assets Annual | 1,778.42 |
| Total Current Assets Annual | 4,681.47 |
| Non Current Assets Annual | 22,732.92 |
| Total Shareholders Funds Annual | 22,970.62 |
| Total Assets Annual | 27,414.39 |
EPS (INR)
Expected
12.55
Reported
12.55
Surprise
0.00%
Jun 2024
EPS beaten by 0.00%
Mar 2024
EPS beaten by 0.00%
Dec 2023
EPS beaten by 0.00%
